Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Nephrology | Urology | Family Medicine
 Disease Category: Benign Prostatic Hyperplasia (Enlarged Prostate)
Location: United States, IN

Trial Information

A Phase III multi-center prospective randomized, parallel-group, placebo-controlled, double-blind, clinical evaluation of NX-1207 for the treatment of BPH (Benign Prostatic Hyperplasia, or Enlarged Prostate)

The purpose of this study is to evaluate the efficacy and safety of NX-1207 and to see if it could be useful for men with BPH. The study treatment will consist of either an injection of NX-1207 or of a placebo into the prostate. If you end up receiving the placebo, you will be offered the chance to receive NX-1207 at the end of the study. The study will last for 12 months.

Inclusions:

  • Male ≥ 45 years of age
  • History of BPH for at least 1 year

Exclusions:

  • Acute or chronic Prostatitis in the past 12 months
  • Urinary Tract Infections more than once in the past 12 months
  • Previous surgical or invasive prostate treatments such as TURP, TUMT, and TUNA, laser or any minimally invasive treatments.
  • History of urinary retention in the past 12 months
  • Prostate or bladder cancer
  • PSA ≥ 10 ng.ml

Debbie Johnson, CCRC, Director of Research
First Urology, PSC. (formerly Metropolitan Urology and Allied Urology)
101 Hospital Blvd.
Jeffersonville, IN 47130
Phone: (812) 206-8161
Fax: (812) 288-2612
Email: djohnson@meturo.com

View Map

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:  
Message:
 

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.